While vulvar cancer is rare, affecting about 1 in 373 women in their lifetime, its subtle signs and rising incidence among Black women make awareness and early detection more critical than ever.
Key Takeaways
- In 2023, approximately 6,470 new cases of invasive vulvar cancer are expected to be diagnosed in the United States among women.
- The lifetime risk of developing vulvar cancer for a woman in the US is about 1 in 373.
- Vulvar cancer accounts for about 0.6% (5 per 100,000 women) of all new cancer cases in the US annually.
- Human papillomavirus (HPV) infection, particularly types 16 and 18, is a major risk factor present in 40-60% of vulvar squamous cell carcinomas.
- Women with a history of cervical intraepithelial neoplasia (CIN) have a 3-5 fold increased risk of vulvar cancer.
- Lichen sclerosus is associated with 30-50% of vulvar squamous cell carcinomas not related to HPV.
- The most common symptom of vulvar cancer is persistent itching in 60-80% of patients at diagnosis.
- A visible vulvar mass or lump is reported in 50% of vulvar cancer cases upon presentation.
- Vulvar bleeding or discharge occurs in 30-40% of patients with invasive disease.
- The primary treatment for early-stage vulvar cancer (IA-IB) is radical wide local excision in 70% of cases.
- Five-year survival for localized vulvar cancer (stage I) is 90% in the US.
- Inguinofemoral lymphadenectomy is performed in 80% of stage II and higher vulvar cancers.
- Regular self-examination detects 40% of vulvar cancers at early stage.
- HPV vaccination (Gardasil 9) prevents 90% of HPV-16/18 related vulvar precancers.
- Smoking cessation reduces vulvar cancer risk by 50% after 10 years.
A rare gynecologic cancer mainly affects older women but can be prevented.
Epidemiology
1In 2023, approximately 6,470 new cases of invasive vulvar cancer are expected to be diagnosed in the United States among women.
Verified2The lifetime risk of developing vulvar cancer for a woman in the US is about 1 in 373.
Verified3Vulvar cancer accounts for about 0.6% (5 per 100,000 women) of all new cancer cases in the US annually.
Verified4Globally, there were an estimated 45,000 new cases of vulvar cancer in 2020.
Directional5The age-adjusted incidence rate of vulvar cancer in the US from 2016-2020 was 2.5 per 100,000 women.
Single source6Incidence rates of vulvar cancer have been stable in the US white population but increasing among black women at 2.1% annually from 2012-2016.
Verified7In Europe, the incidence of vulvar cancer varies from 1.8 per 100,000 in Finland to 3.0 per 100,000 in Denmark.
Verified8Vulvar cancer represents 3-5% of all female genital cancers worldwide.
Verified9In Australia, the age-standardized incidence rate for vulvar cancer is 1.9 per 100,000 women as of 2021.
Directional10Among US women aged 65 and older, vulvar cancer incidence is 18.5 per 100,000.
Single source11In the UK, there were 1,273 new vulvar cancer cases registered in 2019.
Verified12Vulvar cancer is the fourth most common gynecologic cancer in the US after uterine, ovarian, and cervical.
Verified13In India, vulvar cancer constitutes less than 1% of all gynecological malignancies.
Verified14The median age at diagnosis for vulvar cancer in the US is 69 years.
Directional15In Brazil, the incidence rate of vulvar cancer is 1.5 per 100,000 women, with higher rates in the Northeast region.
Single source16Vulvar intraepithelial neoplasia (VIN) precedes invasive vulvar cancer in about 5-10% of cases.
Verified17In the Netherlands, vulvar cancer incidence increased from 1.4 to 2.0 per 100,000 between 1989 and 2017.
Verified18Among Hispanic women in the US, vulvar cancer incidence is 2.2 per 100,000, lower than non-Hispanic whites at 2.6.
Verified19In Japan, vulvar cancer is extremely rare with an incidence of 0.1 per 100,000 women.
Directional20Approximately 45% of vulvar cancers in younger women (<50 years) are HPV-related.
Single source21In Canada, there are about 650 new cases of vulvar cancer each year.
Verified22The incidence of vulvar melanoma, a subtype, is 0.3 per 100,000 women in the US.
Verified23In South Africa, vulvar cancer rates are higher among black women at 4.2 per 100,000.
Verified24Vulvar cancer mortality in the US is about 1,200 deaths per year.
Directional25In Sweden, the incidence has risen 2.5% annually over the past decade.
Single source26Among Asian/Pacific Islander women in the US, incidence is lowest at 1.0 per 100,000.
Verified27In 2020, China reported around 4,500 new vulvar cancer cases.
Verified28Vulvar cancer is diagnosed at a localized stage in 60% of US cases.
Verified29In Italy, the standardized incidence rate is 1.7 per 100,000 women.
Directional30Lifetime prevalence of VIN in the US is estimated at 1 in 1,000 women over 40.
Single sourceEpidemiology Interpretation
Despite its low overall prevalence—roughly the chance of being struck by lightning—vulvar cancer’s rising incidence among specific groups and its late-age diagnosis reveal it as a quietly persistent foe in women's health.
Prevention and Screening
1Regular self-examination detects 40% of vulvar cancers at early stage.
Verified2HPV vaccination (Gardasil 9) prevents 90% of HPV-16/18 related vulvar precancers.
Verified3Smoking cessation reduces vulvar cancer risk by 50% after 10 years.
Verified4Annual vulvar inspection in high-risk women (lichen sclerosus) detects 70% early lesions.
Directional5No routine screening program exists, but opportunistic exam catches 60% asymptomatic cases.
Single source6Topical imiquimod for VIN prevents progression in 45-60% of treated patients.
Verified7Condom use reduces HPV transmission risk by 70% for vulvar exposure.
Verified8Management of lichen sclerosus with steroids reduces cancer risk by 90%.
Verified9HPV vaccine efficacy in women up to age 45 is 80% against persistent infection.
Directional10Biopsy of all persistent vulvar lesions >6 months prevents 80% late diagnoses.
Single source11Population HPV vaccination reduced VIN incidence by 50% in Australia post-2007.
Verified12Weight management in obese women lowers risk by 25% through cohort studies.
Verified13Safe sex practices decrease HPV-related vulvar cancer precursors by 60%.
Verified14Routine gynecologic exams identify 50% of VIN before invasion.
Directional15Avoidance of immunosuppression when possible cuts risk in transplant patients by 30%.
Single source16Photodynamic therapy for VIN has 65% clearance rate, delaying surgery.
Verified17Education on vulvar self-exam improves early detection rates by 35% in trials.
Verified18Vaccination coverage >80% could prevent 85% of HPV-attributable vulvar cancers.
Verified19Treatment of cervical dysplasia reduces subsequent vulvar cancer by 40%.
Directional20Long-term follow-up after VIN excision prevents 70% recurrences with cytology.
Single sourcePrevention and Screening Interpretation
While no single magic bullet exists, this arsenal of actions—from vaccines and vigilance to kicking cigarettes and condom use—shows that vulvar cancer is often a preventable or highly manageable foe when met with a layered and proactive defense.
Risk Factors
1Human papillomavirus (HPV) infection, particularly types 16 and 18, is a major risk factor present in 40-60% of vulvar squamous cell carcinomas.
Verified2Women with a history of cervical intraepithelial neoplasia (CIN) have a 3-5 fold increased risk of vulvar cancer.
Verified3Lichen sclerosus is associated with 30-50% of vulvar squamous cell carcinomas not related to HPV.
Verified4Smoking increases the risk of vulvar cancer by 1.5 to 2.0 times, especially for HPV-related cases.
Directional5Immunosuppression, such as in HIV-positive women, elevates vulvar cancer risk by up to 10-fold.
Single source6Vulvar cancer risk is 4 times higher in women with a history of lower genital tract precancer.
Verified7Obesity (BMI >30) is linked to a 1.8-fold increased risk of vulvar cancer.
Verified8Chronic vulvar inflammation from conditions like lichen planus raises risk by 2-3 times.
Verified9HPV vaccination reduces the risk of HPV-related VIN by over 90% in vaccinated populations.
Directional10Diabetes mellitus is associated with a 1.4 relative risk for vulvar cancer development.
Single source11Women with vulvar intraepithelial neoplasia 3 (VIN3) have a 5-20% progression risk to invasive cancer over 5 years.
Verified12Prior hysterectomy for CIN increases vulvar cancer risk by 2-fold due to field cancerization.
Verified13Genetic syndromes like Lynch syndrome confer a 14-fold increased risk of vulvar cancer.
Verified14Alcohol consumption over 14 units/week raises risk by 1.3 times independently of smoking.
Directional15Multiparity (5+ births) is protective, reducing risk by 20-30% compared to nulliparity.
Single source16HIV infection increases VIN incidence by 5-10 fold in women.
Verified17Use of oral contraceptives for over 10 years slightly elevates risk (RR 1.2).
Verified18Paget's disease of the vulva has a 5-10% risk of underlying invasive carcinoma.
Verified19Organ transplant recipients on immunosuppressants have 4-8 times higher vulvar cancer risk.
Directional20History of smoking cessation reduces risk by 40% after 15 years compared to current smokers.
Single source21Low socioeconomic status correlates with 1.5-fold higher incidence due to screening disparities.
Verified22Familial clustering in HPV-negative cases suggests genetic predisposition in 10-15%.
Verified23Chronic HPV-16 persistence doubles the progression risk from VIN to invasion.
VerifiedRisk Factors Interpretation
While it's a disease shaped by numerous villains—from the ubiquitous HPV and chronic inflammation to potent immunosuppression and even societal inequality—the statistics also offer heroes, like vaccination, smoking cessation, and the body's own resilience in multiparity, creating a complex battlefield where proactive defense is your most powerful weapon.
Symptoms and Diagnosis
1The most common symptom of vulvar cancer is persistent itching in 60-80% of patients at diagnosis.
Verified2A visible vulvar mass or lump is reported in 50% of vulvar cancer cases upon presentation.
Verified3Vulvar bleeding or discharge occurs in 30-40% of patients with invasive disease.
Verified4Pain or burning sensation in the vulva is present in 20-30% at initial diagnosis.
Directional5Biopsy confirmation is required for 95% of suspected vulvar lesions to diagnose cancer.
Single source6Colposcopy of the vulva identifies multifocal lesions in 25% of VIN cases.
Verified7Skin color changes (white, red, or blue) are noted in 70% of vulvar cancer presentations.
Verified8Lymph node metastasis is clinically palpable in 20-30% of early-stage vulvar cancers.
Verified9The FIGO staging system is used in 90% of vulvar cancer diagnoses for prognosis.
Directional10MRI detects groin node involvement with 85-90% accuracy in vulvar cancer staging.
Single source11Vulvoscopy with acetic acid application reveals acetowhite lesions in 80% of VIN.
Verified12Sentinel lymph node biopsy is positive in 10-15% of clinical stage I vulvar cancers.
Verified13PET-CT imaging alters staging in 25% of advanced vulvar cancer cases.
Verified14Open biopsies are performed in 60% of cases, punch in 30%, and excisional in 10%.
Directional15Dysuria or urinary symptoms occur in 10-15% due to urethral involvement.
Single source1685% of vulvar squamous cell carcinomas are keratinizing subtype on histopathology.
Verified17HPV testing on biopsies is positive in 28% of all vulvar SCC cases.
Verified18Ulceration is seen in 40% of invasive vulvar lesions at diagnosis.
Verified19TNM staging shows T1 tumors (≤2cm) in 45% of cases at presentation.
Directional20Cytology from vulvar lesions has 70% sensitivity for high-grade VIN detection.
Single sourceSymptoms and Diagnosis Interpretation
While the most common alarm bell is a maddening itch, the full diagnostic symphony of vulvar cancer—from visible lumps and color changes to the critical, sobering biopsies and scans—reveals a disease that often whispers before it shouts, demanding keen attention to its varied and persistent cues.
Treatment and Outcomes
1The primary treatment for early-stage vulvar cancer (IA-IB) is radical wide local excision in 70% of cases.
Verified2Five-year survival for localized vulvar cancer (stage I) is 90% in the US.
Verified3Inguinofemoral lymphadenectomy is performed in 80% of stage II and higher vulvar cancers.
Verified4Radiation therapy is used adjuvantly in 50% of node-positive cases post-surgery.
Directional5Overall 5-year survival for all stages of vulvar cancer is 71% in the US (2013-2019).
Single source6Chemoradiation with cisplatin improves survival by 15% in locally advanced disease.
Verified7Sentinel lymph node procedure reduces lymphedema risk to 5% vs 30% with full lymphadenectomy.
Verified8Recurrence rate after surgery for stage I is 5-10% within 5 years.
Verified9Neoadjuvant chemotherapy response rate is 50% in bulky stage III/IVA tumors.
Directional105-year survival drops to 40% for regional stage (node-positive) vulvar cancer.
Single source11Radical vulvectomy is performed in only 10% of modern cases due to fertility-preserving options.
Verified12Groin recurrence after negative sentinel node is 2-3% in large trials.
Verified13Immunotherapy (pembrolizumab) shows 10-15% response in recurrent MSI-high vulvar cancers.
Verified14Postoperative radiation reduces local recurrence by 50% in high-risk margins (<8mm).
Directional15Distant metastasis-free survival at 5 years is 80% for stage I-II treated optimally.
Single source16Exenteration for central recurrence has 30-50% 5-year survival in selected cases.
Verified17Targeted therapy against PIK3CA mutations benefits 20% of vulvar SCC patients.
Verified18Lymphedema incidence post-radiation and surgery is 25-40% in advanced cases.
Verified195-year survival for metastatic vulvar cancer (stage IV) is under 20%.
Directional20Laser ablation for VIN has 70% recurrence-free rate at 2 years.
Single source21HPV vaccination prior to treatment does not affect outcomes but prevents new lesions in 80%.
Verified22Wound complication rate after vulvectomy is 20-30%, higher in diabetics.
Verified23Overall survival improvement of 10% seen with multidisciplinary care teams.
Verified24HPV-based vulvar cancer has better 5-year survival (75%) vs non-HPV (65%).
DirectionalTreatment and Outcomes Interpretation
While survival rates shine brightly for early, localized cases, the journey through advanced vulvar cancer reveals a sobering landscape of escalating interventions and diminishing odds, starkly highlighting that prevention and earliest possible detection are the truest victories.
Sources & References
- Reference 1CANCERcancer.orgVisit source
- Reference 2CANCERcancer.govVisit source
- Reference 3SEERseer.cancer.govVisit source
- Reference 4GCOgco.iarc.who.intVisit source
- Reference 5PUBMEDpubmed.ncbi.nlm.nih.govVisit source
- Reference 6NCBIncbi.nlm.nih.govVisit source
- Reference 7WHOwho.intVisit source
- Reference 8AIHWaihw.gov.auVisit source
- Reference 9CANCERRESEARCHUKcancerresearchuk.orgVisit source
- Reference 10ACOGacog.orgVisit source
- Reference 11CANCERcancer.caVisit source
- Reference 12MAYOCLINICmayoclinic.orgVisit source
- Reference 13CDCcdc.govVisit source